Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;476(11):4081-4092.
doi: 10.1007/s11010-021-04221-2. Epub 2021 Jul 17.

Exosomal noncoding RNAs: key players in glioblastoma drug resistance

Affiliations
Review

Exosomal noncoding RNAs: key players in glioblastoma drug resistance

Ahmad Movahedpour et al. Mol Cell Biochem. 2021 Nov.

Abstract

Glioma, as one of the most severe human malignancies, is defined as the Central Nervous System's (CNS) tumors. Glioblastoma (GBM) in this regard, is the most malignant type of gliomas. There are multiple therapeutic strategies to cure GBM, for which chemotherapy is often the first-line treatment. Still, various cellular processes, such as uncontrolled proliferation, invasion and metastasis, may disturb the treatment efficacy. Drug resistance is another process in this way, which can also cause undesirable effects. Thereupon, identifying the mechanisms, involved in developing drug resistance and the relevant mechanisms can be very helpful in GBM management. The discovery of exosomal non-coding RNAs (ncRNAs), RNA molecules that can be transferred between the cells and different tissues using the exosomes, was a milestone in this regard. It has been revealed that the key exosomal ncRNAs, including circular RNAs, microRNAs, and long ncRNAs, are able to modulate GBM drug resistance through different signaling pathways or by affecting regulatory proteins and their corresponding genes. Nowadays, researchers are trying to overcome the limitations of chemotherapy by targeting these RNA molecules. Accordingly, this review aims to clarify the substantial roles of exosomal ncRNAs in GBM drug resistance and involved mechanisms.

Keywords: Drug resistance; Exosomes; Glioblastoma; Noncoding RNAs.

PubMed Disclaimer

References

    1. Bark JM, Kulasinghe A, Chua B, Day BW, Punyadeera C (2020) Circulating biomarkers in patients with glioblastoma. Br J Cancer 122(3):295–305 - DOI
    1. Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820 - PubMed - DOI - PMC
    1. Le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P et al (2019) Molecular targeted therapy of glioblastoma. Cancer Treat Rev 80:101896 - PubMed - DOI - PMC
    1. Alexander BM, Cloughesy TF (2017) Adult glioblastoma. J Clin Oncol 35(21):2402–2409 - PubMed - DOI - PMC
    1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17(4):iv1–iv62 - PubMed - PMC - DOI

LinkOut - more resources